S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
NASDAQ:NKTX

Nkarta (NKTX) Stock Price, News & Analysis

$7.29
-0.50 (-6.42%)
(As of 04/19/2024 08:51 PM ET)
Today's Range
$7.18
$7.96
50-Day Range
$7.29
$15.71
52-Week Range
$1.28
$16.24
Volume
731,000 shs
Average Volume
1.92 million shs
Market Capitalization
$360.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.83

Nkarta MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
144.6% Upside
$17.83 Price Target
Short Interest
Bearish
9.81% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$20 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.34) to ($2.30) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.72 out of 5 stars

Medical Sector

407th out of 907 stocks

Pharmaceutical Preparations Industry

181st out of 419 stocks

NKTX stock logo

About Nkarta Stock (NASDAQ:NKTX)

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

NKTX Stock Price History

NKTX Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
TD Cowen Reaffirms Their Buy Rating on Nkarta (NKTX)
Nkarta: NK Cell Therapy Advancement On Two Fronts
Nkarta Prices $240 Mln Offering; Stock Up Over 16%
Nkarta’s Strategic Focus and Financial Strength Underpin Buy Rating
NKTX Stock Earnings: Nkarta Beats EPS for Q4 2023
See More Headlines
Receive NKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
4/21/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NKTX
Fax
N/A
Employees
150
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.83
High Stock Price Target
$25.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+144.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-117,500,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.57 per share

Miscellaneous

Free Float
46,649,000
Market Cap
$360.27 million
Optionable
Optionable
Beta
0.70
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Paul J. HastingsMr. Paul J. Hastings (Age 64)
    CEO, President & Director
    Comp: $938.41k
  • Dr. Alicia J. Hager (Age 54)
    Chief Legal Officer & Corporate Secretary
    Comp: $590.94k
  • Ms. Alyssa Levin C.A. (Age 39)
    CPA, Chief Financial & Business Officer and Principal Accounting Officer
  • Dr. Ralph Brandenberger Ph.D. (Age 55)
    Chief Technical Officer
  • Dr. James Trager Ph.D. (Age 61)
    Chief Scientific Officer
  • Mr. Greg Mann
    Vice President of Public Affairs and Investor Relations
  • Dr. David R. Shook M.D. (Age 46)
    Chief Medical Officer

NKTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Nkarta stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nkarta in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NKTX shares.
View NKTX analyst ratings
or view top-rated stocks.

What is Nkarta's stock price target for 2024?

5 equities research analysts have issued 12-month price targets for Nkarta's shares. Their NKTX share price targets range from $15.00 to $25.00. On average, they anticipate the company's share price to reach $17.83 in the next twelve months. This suggests a possible upside of 144.6% from the stock's current price.
View analysts price targets for NKTX
or view top-rated stocks among Wall Street analysts.

How have NKTX shares performed in 2024?

Nkarta's stock was trading at $6.60 at the beginning of 2024. Since then, NKTX shares have increased by 10.5% and is now trading at $7.29.
View the best growth stocks for 2024 here
.

When is Nkarta's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our NKTX earnings forecast
.

How were Nkarta's earnings last quarter?

Nkarta, Inc. (NASDAQ:NKTX) posted its quarterly earnings data on Thursday, March, 21st. The company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.05.

What other stocks do shareholders of Nkarta own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nkarta investors own include Axcella Health (AXLA), Cronos Group (CRON), Block (SQ), Advanced Micro Devices (AMD), ASML (ASML), Beyond Meat (BYND), Citigroup (C), Salesforce (CRM), CVS Health (CVS) and DraftKings (DKNG).

When did Nkarta IPO?

Nkarta (NKTX) raised $150 million in an initial public offering on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities served as the underwriters for the IPO.

Who are Nkarta's major shareholders?

Nkarta's stock is owned by a variety of institutional and retail investors. Top institutional investors include Wasatch Advisors LP (2.36%) and Denali Advisors LLC (0.05%). Insiders that own company stock include David Shook, Dawn N Edwards, James Trager, Kanya Rajangam, Nadir Mahmood, Paul J Hastings, Paul J Hastings, Ra Capital Management, LP, Ralph Brandenberger and Simeon George.
View institutional ownership trends
.

How do I buy shares of Nkarta?

Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NKTX) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners